Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Andrew Warwick Hamer Buys 18,900 Shares

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Andrew Warwick Hamer bought 18,900 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were acquired at an average price of C$1.88 per share, for a total transaction of C$35,606.69.

Cardiol Therapeutics Price Performance

TSE CRDL remained flat at C$1.80 during trading hours on Tuesday. The company’s stock had a trading volume of 7,700 shares, compared to its average volume of 134,125. The stock has a market capitalization of C$125.78 million, a PE ratio of -4.09 and a beta of 0.70. Cardiol Therapeutics Inc. has a 52 week low of C$1.09 and a 52 week high of C$4.26. The stock has a 50 day moving average price of C$2.36 and a 200-day moving average price of C$2.68. The company has a current ratio of 2.39, a quick ratio of 6.84 and a debt-to-equity ratio of 1.07.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.